
Oncology NEWS International
- Oncology NEWS International Vol 16 No 10
- Volume 16
- Issue 10
Taxotere combination approved for induction therapy in SCCHN
FDA has approved Sanofi-Aventis' Taxotere (docetaxel) for use in combination with cisplatin and fluorouracil (TPF) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
ROCKVILLE, MarylandFDA has approved Sanofi-Aventis' Taxotere (docetaxel) for use in combination with cisplatin and fluorouracil (TPF) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
FDA based its approval on TAX- 324, a multicenter, open-label, randomized trial of 501 patients. Overall survival was significantly prolonged with the Taxotere-containing regimen, compared with PF alone (P = .0058). Median survival was 70.6 months in the TPF group vs 30.1 months in the PF group (HR 0.70).
Articles in this issue
over 18 years ago
Bill aims to 'revitalize' FDA by adding powers and databasesover 18 years ago
New myeloma trial results; two new studies initiatedover 18 years ago
Neoadjuvant trastuzumab increases pCR ratesover 18 years ago
Court rejects right of terminally ill to unproven drugsover 18 years ago
Sorafenib improves overall survival in Asian HCC ptsover 18 years ago
Skipping tam doses increases risk of deathover 18 years ago
The SGR: The madness behind physician payment fee cutsover 18 years ago
Dr. Pegram seeks new breast cancer challenges at Miamiover 18 years ago
SearchMedica.com receives awardNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































